To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...
After five years of Evrysdi, people with SMA types 2 and 3 are continuing to show stabilization and improvement in motor ...
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...
Barchart on MSN2d
How Is Biogen's Stock Performance Compared to Other Biotech Stocks?With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and ...
Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...
The SMA gene therapy candidate OAV101 IT, a version of Zolgensma, can be safely given to previously treated patients, per new ...
Detailed price information for Camp4 Therapeutics Corp (CAMP-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback